Physician profile

Daniel L Wiernik

Foot and Ankle Surgery · Orlando, FL

NPI 1275504110

$2,007.71

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$436.36

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Reel Surgical, INC. $1,225.50 2022
Stryker Corporation $250.15 2019-2023 Infinity
Arthrex, INC. $182.98 2024
Linvatec Corporation $153.60 2023 Biobrace 23mm
Paratek Pharmaceuticals, INC. $108.77 2022
Curonix LLC $32.25 2023 Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A
Wright Medical Technology, INC. $29.85 2019
Kowa Pharmaceuticals America, INC. $13.41 2022
Embody, INC. $11.20 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel L Wiernik

$2,007.71

in general payments reported 2019-2025

Years
2019-2024
Top company
Reel Surgical, INC.

https://glasscript.com/doctor/797494/daniel-l-wiernik

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.